ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma
Ken Tanaka(University of Tsukuba), Hiroyuki Nishiyama(University of Tsukuba)
Cited by 42
Related Papers
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388